Risk factors

Prokidney (PROK) risk factors

Item 1A of every Prokidney Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open PROK in Gloom →
Prokidney's chart, financials and news, free in your browser.Open PROK in Gloom →
  • FY2025 10-K risk factors
    107 risks11 new14 dropped19 reworded

    ProKidney added commercialization risks regarding rilparencel, manufacturing vulnerabilities, and potential NASDAQ delisting.

    Filed Mar 18, 2026
  • FY2024 10-K risk factors
    110 risks

    ProKidney has no revenue and recurring net losses, reporting $163.3 million in net losses for 2024. The business depends entirely on developing and commercializing its lead cell therapy candidate, rilparencel, for chronic kidney disease. Manufacturing is complex, centralized in Winston-Salem, and relies on patient-specific autologous cells and specialized cryopreservation.

    Filed Mar 17, 2025